RiverVest Venture Partners

Investing in Life Science Innovation

 

News

Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-Class Profile

Phase 1 Clinical Trial to Evaluate AO-176 for the Treatment of Patients with Select Solid Tumors

BRISBANE, Calif. & ST. LOUIS, Mo.–(BUSINESS WIRE)– Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of next-generation anti-CD47 antibody therapies for cancer, today announced the initiation of a new Phase 1 clinical trial of AO-176 in select solid tumors with the first patient dosed. AO-176 is an anti-CD47 antibody with a best-in-class profile that works by blocking the “don’t eat me” signal and also by directly killing tumor cells, with preferential binding to tumor versus normal cells.

VentureMed Group Names J. Robert Paulson Jr. Chief Executive Officer

Toledo, Ohio, February 5, 2019 – VentureMed Group, Inc. a privately-held medical device company that develops and markets the FLEX Vessel Prep™ System to treat peripheral arterial disease (PAD) and stenoses of arteriovenous (AV) fistulas and grafts, announced today that J. Robert Paulson, Jr., has been appointed president and chief executive officer, and a member of the Company’s board of directors, effective January 1, 2019.

Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases

Maralixibat Phase 2b study interim analysis suggests proof of concept in Alagille Synrdome

Combined leadership from former Lumena and Tobira teams to pursue registration in Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis and other liver diseases

SAN DIEGO – Nov. 7, 2018– Mirum Pharmaceuticals today announced that the company has secured $120 million in Series A financing, the proceeds of which will support development of maralixibat for rare cholestatic liver diseases.

Cardialen Closes $17 Million Series B Financing for Heart Rhythm Therapy

Cardialen is developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm

Minneapolis, Oct. 10, 2018 – Cardialen, Inc., a medical device company developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm, announced today the closing of a $17 million Series B investment led by RiverVest Venture Partners, along with Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital. The financing will be used to advance Cardialen’s clinical program with further human testing of its unpinning termination (UPT) therapy and begin development of an implantable device.

OncoResponse Raises $40 Million in Series B Financing

— Adds RiverVest Venture Partners, Qatar Investment Authority and Redmile Group to List of Financial Backers
— Proceeds Will Advance Growing Portfolio of Therapeutic Candidates for Various Cancers

SEATTLE, Washington – September 11, 2018 – OncoResponse, an immunotherapy company developing a portfolio of novel antibodies to high-value targets for the treatment of cancer, today announced the completion of a $40 million series B equity financing. Participants in the round, which was led by RiverVest Venture Partners, included new investors Qatar Investment Authority (QIA) and Redmile Group, and existing investors Alexandria Venture Investments, ARCH Venture Partners, HT Family Office, Canaan Partners, Helsinn Investment Fund and William Marsh Rice University.

Allakos Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN CARLOS, Calif., July 24, 2018 (GLOBE NEWSWIRE) — Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various eosinophil and mast cell related diseases, today announced the closing of its initial public offering of 8,203,332 shares of its common stock, sold by the Company at a public offering price of $18.00 per share.

Allakos Announces Pricing of Initial Public Offering

SAN CARLOS, Calif., July 19, 2018 (GLOBE NEWSWIRE) — Allakos Inc., (Nasdaq:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various eosinophil and mast cell related diseases, today announced the pricing of its initial public offering of 7,133,333 shares of its common stock at a public offering price of $18.00 per share, for total gross proceeds of approximately $128.4 million, before deducting underwriting discounts and commissions and other offering expenses.

Newsletter Sign Up